Balkan Journal of Medical Genetics

INTERLEUKIN-18 PROMOTER GENE POLYMORPHISMS ARE NOT ASSOCIATED WITH MYOCARDIAL INFARCTION IN TYPE 2 DIABETES IN SLOVENIA
Kariž S1*, Petrovič D2
*Corresponding Author: Stojan Kariž, Department of Internal Medicine, General Hospital Izola, Polje 35, Izola 6310, Slovenia; Tel.: +386-5-660-6480; Fax: +386-660-6305; E-mail: stojan.kariz@siol.net
page: 3

RESULTS

The clinical characteristics of the subjects and controls are listed in Table 1. The former were younger, predominantly male and had a higher incidence of cigarette smoking compared to the control group. They also had higher total cholesterol and LDL cholesterol levels, and longer duration of type 2 diabetes than the controls. The high sensitivity CRP serum levels were also higher in the diabetic patients with MI. There were no significant differences in the prevalence of hypertension, mean blood pressure, and mean BMI, and serum HDL cholesterol, triglyceride, and Hb A1c levels between the two groups. Therapy for diabetes was similar in both groups. The IL-18 genotype distributions in MI and control groups were compatible with Hardy-Weinberg expectations (–607: MI group χ2 = 0.40, p = 0.53; controls χ2 = 1.65, p = 0.2; –137: MI group χ2 = 0.02, p = 0.89; controls χ2 = 1.07, p = 0.3). The distribution of genotypes in the promoter of the IL-18 gene in MI and in control groups are shown in Table 2. There were no differences between the two groups. The serum IL-18 level in 70 diabetics did not differ significantly from those of 22 controls without diabetes (310.0 ± 234.1 ng/L vs. 250.3 ± 190.4 ng/L; p = 0.3). However, the level in 20 diabetics with MI was statistically significantly higher than that of 50 diabetics without CAD (534.0 ± 397.5 ng/L vs. 286.2 ± 202.4 ng/l; p <0.01). A significant difference in IL-18 serum levels was found in diabetics with the –137 CC genotype (10 subjects) compared to those with CG+GG genotypes (60 subjects) (241.5 ± 132.7 ng/L vs. 340.2 ± 167.4 ng/L; p <0.05). We found no significant difference in IL-18 level in diabetics with the –607 CC genotype (17 subjects) compared to those with CA+AA genotypes (53 subjects) (287.3 ± 221.7 ng/L vs. 323.3 ± 257.3 ng/L; p = 0.6).

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact